Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II perioperative FOLFOX + cetuximab ± bevacizumab for resectable liver metastases from colorectal cancer
2005-002825-29Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab, bevacizumab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Primary feasibility and safety and Primary activity. Started May 2006; status: completed.
02
Drugs
cetuximabbevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-002825-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002825-29.